Last reviewed · How we verify

NCT05149885

A Feasibility Study of SenseGuard to Assess Airway Responsiveness During Methacholine Challenge Test (MCT)

Completed NA Last updated 26 March 2024
What this trial tests

NA trial testing SenseGuard monitoring in Asthma in 37 participants. Completed in 1 June 2023.

Timeline
4 November 2021
Primary endpoint
25 March 2023
1 June 2023

Quick facts

Lead sponsorNanoVation
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposediagnostic
Enrollment37
Start date4 November 2021
Primary completion25 March 2023
Estimated completion1 June 2023
Sites1 location across Cyprus

Drugs / interventions tested

Conditions studied

Sponsor

NanoVation

Who can join

18 and older, any sex, with Asthma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

SenseGuard (SG) is an innovative device for respiratory monitoring. At this study SG measurement will be integrated in a Methacholine Challenge Test (MCT) for monitoring changes in airway obstruction occurred during MCT in parallel to spirometry.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Asthma

Currently open trials in the same condition.

Other NanoVation trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05149885.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing